[{"id":"53f4eddd-132e-4531-8be4-d3f2264f7d40","acronym":"","url":"https://clinicaltrials.gov/study/NCT06790797","created_at":"2025-02-25T18:39:59.893Z","updated_at":"2025-02-25T18:39:59.893Z","phase":"","brief_title":"Investigating the Biomarkers in Tumor and Peripheral Blood to Evaluate the Efficacy of Cancer Immunotherapy in Chest Cancer Patients","source_id_and_acronym":"NCT06790797","lead_sponsor":"Zhao Jun","biomarkers":" CD8 • IFNG • IL2RA • CD4 • CD69 • TNFRSF9 • FOXP3 • ENTPD1","pipe":"","alterations":" ","tags":["CD8 • IFNG • IL2RA • CD4 • CD69 • TNFRSF9 • FOXP3 • ENTPD1"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 02/12/2023","start_date":" 02/12/2023","primary_txt":" Primary completion: 07/30/2027","primary_completion_date":" 07/30/2027","study_txt":" Completion: 07/30/2027","study_completion_date":" 07/30/2027","last_update_posted":"2025-01-24"},{"id":"125d17e4-ca45-476f-90d3-c73d72c2a455","acronym":"REVOLUTION","url":"https://clinicaltrials.gov/study/NCT03891485","created_at":"2021-01-17T18:04:44.611Z","updated_at":"2024-07-02T16:35:12.700Z","phase":"","brief_title":"Nivolumab in mRCC Patients: Treg Function, T-cell Access and NK Interactions to Predict and Improve Efficacy","source_id_and_acronym":"NCT03891485 - REVOLUTION","lead_sponsor":"National Cancer Institute, Naples","biomarkers":" PD-L1 • IFNG • CD73 • IL10 • ENTPD1","pipe":"","alterations":" ","tags":["PD-L1 • IFNG • CD73 • IL10 • ENTPD1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 12/01/2016","start_date":" 12/01/2016","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2024-03-26"},{"id":"b27e5854-9657-4b24-a83c-b4bf33177792","acronym":"","url":"https://clinicaltrials.gov/study/NCT03884556","created_at":"2021-01-18T19:08:40.399Z","updated_at":"2025-02-25T16:15:48.685Z","phase":"Phase 1","brief_title":"TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers","source_id_and_acronym":"NCT03884556","lead_sponsor":"Trishula Therapeutics, Inc.","biomarkers":" ENTPD1","pipe":" | ","alterations":" ENTPD1 expression","tags":["ENTPD1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ENTPD1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • gemcitabine • docetaxel • albumin-bound paclitaxel • eltivutabart (TTX-030)"],"overall_status":"Completed","enrollment":" Enrollment 56","initiation":"Initiation: 04/10/2019","start_date":" 04/10/2019","primary_txt":" Primary completion: 11/30/2022","primary_completion_date":" 11/30/2022","study_txt":" Completion: 09/29/2023","study_completion_date":" 09/29/2023","last_update_posted":"2023-10-04"},{"id":"58ad1cf0-b0ae-467d-991a-a5d900291a36","acronym":"IMMUVIX","url":"https://clinicaltrials.gov/study/NCT03255252","created_at":"2021-01-18T16:04:49.386Z","updated_at":"2024-07-02T16:35:46.214Z","phase":"Phase 2","brief_title":"Assessment Study to Evaluate Specific Immune Response in Locally Advanced Cervix Cancer After Radio-chemotherapy","source_id_and_acronym":"NCT03255252 - IMMUVIX","lead_sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","biomarkers":" CD8 • PD-1 • HAVCR2 • CD4 • ENTPD1","pipe":" | ","alterations":" PD-1 expression • CD8 expression • ENTPD1 expression","tags":["CD8 • PD-1 • HAVCR2 • CD4 • ENTPD1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-1 expression • CD8 expression • ENTPD1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 07/15/2017","start_date":" 07/15/2017","primary_txt":" Primary completion: 06/16/2022","primary_completion_date":" 06/16/2022","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2023-06-07"},{"id":"2d513838-1520-48c5-95c6-510610c1ab07","acronym":"","url":"https://clinicaltrials.gov/study/NCT05789498","created_at":"2023-03-29T14:03:25.617Z","updated_at":"2024-07-02T16:35:52.066Z","phase":"","brief_title":"Investigating the Biomarkers in Tumor and Peripheral Blood to Evaluate the Efficacy of Cancer Immunotherapy in Chest Cancer Patients","source_id_and_acronym":"NCT05789498","lead_sponsor":"Zhao Jun","biomarkers":" PD-L1 • CD8 • IFNG • IL2RA • CD4 • CD69 • TNFRSF9 • FOXP3 • ENTPD1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • CD8 • IFNG • IL2RA • CD4 • CD69 • TNFRSF9 • FOXP3 • ENTPD1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 02/12/2023","start_date":" 02/12/2023","primary_txt":" Primary completion: 03/30/2024","primary_completion_date":" 03/30/2024","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2023-03-29"},{"id":"5a2242ee-9189-4e75-8e69-0041e4514703","acronym":"Apollo","url":"https://clinicaltrials.gov/study/NCT05761132","created_at":"2023-03-09T15:01:27.449Z","updated_at":"2024-07-02T16:35:53.672Z","phase":"Phase 2","brief_title":"Neo-adjuvant Pembrolizumab in Vulvar Squamous Cell Carcinoma: a Clinical Proof-of-concept Study","source_id_and_acronym":"NCT05761132 - Apollo","lead_sponsor":"Leiden University Medical Center","biomarkers":" PD-L1 • PD-1 • CD4 • ITGAE • ENTPD1","pipe":" | ","alterations":" ENTPD1 expression","tags":["PD-L1 • PD-1 • CD4 • ITGAE • ENTPD1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ENTPD1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 04/01/2023","start_date":" 04/01/2023","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2023-03-09"},{"id":"4440793a-ab83-4b82-b144-f3e5b46b6fe3","acronym":"","url":"https://clinicaltrials.gov/study/NCT05748704","created_at":"2023-03-01T15:01:57.757Z","updated_at":"2024-07-02T16:35:54.508Z","phase":"Phase 1","brief_title":"Metabolic and Immunological Effects of a Modified Fasting Regimen in Cancer Patients","source_id_and_acronym":"NCT05748704","lead_sponsor":"University of Genova","biomarkers":" CD8 • IL6 • TNFA • IL2RA • PTPRC • IGF1 • NCAM1 • ENTPD1 • IGFBP3 • IL1B • IGFBP1 • ISG20 • LEP","pipe":"","alterations":" ","tags":["CD8 • IL6 • TNFA • IL2RA • PTPRC • IGF1 • NCAM1 • ENTPD1 • IGFBP3 • IL1B • IGFBP1 • ISG20 • LEP"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 11/01/2021","start_date":" 11/01/2021","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2023-03-01"},{"id":"30aef5c9-4186-4030-80ca-8f512afdcdbc","acronym":"IOSCAR","url":"https://clinicaltrials.gov/study/NCT04624828","created_at":"2021-01-19T20:35:18.695Z","updated_at":"2024-07-02T16:35:56.368Z","phase":"","brief_title":"Immune Response Evaluation in Oligorecurrent and Oligoprogressive Prostate Cancer Patients Treated With SBRT","source_id_and_acronym":"NCT04624828 - IOSCAR","lead_sponsor":"Istituto Clinico Humanitas","biomarkers":" PD-1 • HAVCR2 • IL2RA • TIGIT • CD36 • CD24 • ENTPD1 • KLRG1 • CEACAM8 • ISG20","pipe":"","alterations":" ","tags":["PD-1 • HAVCR2 • IL2RA • TIGIT • CD36 • CD24 • ENTPD1 • KLRG1 • CEACAM8 • ISG20"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 10/19/2020","start_date":" 10/19/2020","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2023-02-06"},{"id":"ed45cc8a-5b1f-4212-bf7f-555eb5b9a4a1","acronym":"LUNGadenosine","url":"https://clinicaltrials.gov/study/NCT05648188","created_at":"2022-12-13T14:58:00.644Z","updated_at":"2024-07-02T16:35:59.218Z","phase":"","brief_title":"A2R and Ectonucleotidases Expression in Lung Cancer Circulating Tumor Cells","source_id_and_acronym":"NCT05648188 - LUNGadenosine","lead_sponsor":"Centre Hospitalier Universitaire de Nice","biomarkers":" NT5E • ENTPD1","pipe":" | ","alterations":" CD73 expression • ENTPD1 expression","tags":["NT5E • ENTPD1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD73 expression • ENTPD1 expression"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 01/01/2023","start_date":" 01/01/2023","primary_txt":" Primary completion: 10/30/2024","primary_completion_date":" 10/30/2024","study_txt":" Completion: 10/30/2024","study_completion_date":" 10/30/2024","last_update_posted":"2022-12-13"},{"id":"d7c33d28-bc2c-488a-ae44-8439d7424f2f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05508373","created_at":"2022-08-19T17:10:11.974Z","updated_at":"2024-07-02T16:36:05.136Z","phase":"Phase 1","brief_title":"A Clinical Study to Evaluate the Safety, Tolerability,JS019 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05508373","lead_sponsor":"Suzhou Kebo Ruijun Biotechnology Co., Ltd","biomarkers":" ENTPD1","pipe":"","alterations":" ","tags":["ENTPD1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JS019"],"overall_status":"Recruiting","enrollment":" Enrollment 72","initiation":"Initiation: 03/29/2022","start_date":" 03/29/2022","primary_txt":" Primary completion: 06/15/2024","primary_completion_date":" 06/15/2024","study_txt":" Completion: 08/10/2024","study_completion_date":" 08/10/2024","last_update_posted":"2022-08-19"},{"id":"9e2f5cfc-1303-4139-8875-5758a715f3c6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05374226","created_at":"2022-05-16T13:53:38.129Z","updated_at":"2024-07-02T16:36:10.410Z","phase":"Phase 1","brief_title":"A Phase 1 Study to Evaluate JS019 in Advanced Solid Tumors or Lymphomas","source_id_and_acronym":"NCT05374226","lead_sponsor":"Suzhou Kebo Ruijun Biotechnology Co., Ltd","biomarkers":" ENTPD1","pipe":"","alterations":" ","tags":["ENTPD1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JS019"],"overall_status":"Recruiting","enrollment":" Enrollment 172","initiation":"Initiation: 03/31/2022","start_date":" 03/31/2022","primary_txt":" Primary completion: 12/11/2023","primary_completion_date":" 12/11/2023","study_txt":" Completion: 03/07/2024","study_completion_date":" 03/07/2024","last_update_posted":"2022-05-16"},{"id":"f0fc99b5-d1de-433b-93c4-9263a9eb22b3","acronym":"BIOREN","url":"https://clinicaltrials.gov/study/NCT03628859","created_at":"2021-01-18T17:49:29.058Z","updated_at":"2024-07-02T16:36:15.363Z","phase":"","brief_title":"BIOREN (Predictive BIOmarkers in Metastatic RENal Cancer)","source_id_and_acronym":"NCT03628859 - BIOREN","lead_sponsor":"Centre Leon Berard","biomarkers":" IFNG • IL2RA • CD69 • NCAM1 • IL10 • ENTPD1 • B3GAT1 • ISG20 • KLRC1","pipe":"","alterations":" ","tags":["IFNG • IL2RA • CD69 • NCAM1 • IL10 • ENTPD1 • B3GAT1 • ISG20 • KLRC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • sunitinib"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 12/21/2018","start_date":" 12/21/2018","primary_txt":" Primary completion: 06/01/2023","primary_completion_date":" 06/01/2023","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2022-03-15"},{"id":"89da62c1-fcd1-4c88-9d17-a3bb45b0ac16","acronym":"","url":"https://clinicaltrials.gov/study/NCT02567929","created_at":"2021-01-18T12:26:32.431Z","updated_at":"2024-07-02T16:37:11.893Z","phase":"","brief_title":"Assessment of the Anesthetic Effect on the Activity of Immune Cell in Patient With Breast Cancer","source_id_and_acronym":"NCT02567929","lead_sponsor":"Konkuk University Medical Center","biomarkers":" CD73 • ENTPD1","pipe":"","alterations":" ","tags":["CD73 • ENTPD1"],"overall_status":"Completed","enrollment":" Enrollment 218","initiation":"Initiation: 03/01/2016","start_date":" 03/01/2016","primary_txt":" Primary completion: 12/01/2016","primary_completion_date":" 12/01/2016","study_txt":" Completion: 12/01/2016","study_completion_date":" 12/01/2016","last_update_posted":"2018-04-02"}]